New Diagnostic Tool for Metastatic Prostate Cancer Advances Following License Agreement

New Diagnostic Tool for Metastatic Prostate Cancer Advances Following License Agreement
The development of CTT1057, a new product for the diagnosis of metastatic prostate cancer, received a boost with the worldwide license agreement between Novartis-held company Advanced Accelerator Applications (AAA) and Cancer Targeted Technology (CTT). Men with prostate cancer typically show elevated blood levels of prostate-specific antigen (PSA). Screening for PSA levels is common in men who have no symptoms, as well as in those with an already confirmed diagnosis of prostate cancer. But PSA is not accurate enough to diagnose prostate cancer, and better methods are needed. 
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *